1047 related articles for article (PubMed ID: 19881547)
1. Immunogenic death of colon cancer cells treated with oxaliplatin.
Tesniere A; Schlemmer F; Boige V; Kepp O; Martins I; Ghiringhelli F; Aymeric L; Michaud M; Apetoh L; Barault L; Mendiboure J; Pignon JP; Jooste V; van Endert P; Ducreux M; Zitvogel L; Piard F; Kroemer G
Oncogene; 2010 Jan; 29(4):482-91. PubMed ID: 19881547
[TBL] [Abstract][Full Text] [Related]
2. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress.
Martins I; Kepp O; Schlemmer F; Adjemian S; Tailler M; Shen S; Michaud M; Menger L; Gdoura A; Tajeddine N; Tesniere A; Zitvogel L; Kroemer G
Oncogene; 2011 Mar; 30(10):1147-58. PubMed ID: 21151176
[TBL] [Abstract][Full Text] [Related]
3. Immunogenic cancer cell death: a key-lock paradigm.
Tesniere A; Apetoh L; Ghiringhelli F; Joza N; Panaretakis T; Kepp O; Schlemmer F; Zitvogel L; Kroemer G
Curr Opin Immunol; 2008 Oct; 20(5):504-11. PubMed ID: 18573340
[TBL] [Abstract][Full Text] [Related]
4. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy.
Apetoh L; Ghiringhelli F; Tesniere A; Criollo A; Ortiz C; Lidereau R; Mariette C; Chaput N; Mira JP; Delaloge S; André F; Tursz T; Kroemer G; Zitvogel L
Immunol Rev; 2007 Dec; 220():47-59. PubMed ID: 17979839
[TBL] [Abstract][Full Text] [Related]
5. High mobility group box 1 released from necrotic cells enhances regrowth and metastasis of cancer cells that have survived chemotherapy.
Luo Y; Chihara Y; Fujimoto K; Sasahira T; Kuwada M; Fujiwara R; Fujii K; Ohmori H; Kuniyasu H
Eur J Cancer; 2013 Feb; 49(3):741-51. PubMed ID: 23040637
[TBL] [Abstract][Full Text] [Related]
6. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy.
Dong Xda E; Ito N; Lotze MT; Demarco RA; Popovic P; Shand SH; Watkins S; Winikoff S; Brown CK; Bartlett DL; Zeh HJ
J Immunother; 2007 Sep; 30(6):596-606. PubMed ID: 17667523
[TBL] [Abstract][Full Text] [Related]
7. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
Apetoh L; Ghiringhelli F; Tesniere A; Obeid M; Ortiz C; Criollo A; Mignot G; Maiuri MC; Ullrich E; Saulnier P; Yang H; Amigorena S; Ryffel B; Barrat FJ; Saftig P; Levi F; Lidereau R; Nogues C; Mira JP; Chompret A; Joulin V; Clavel-Chapelon F; Bourhis J; André F; Delaloge S; Tursz T; Kroemer G; Zitvogel L
Nat Med; 2007 Sep; 13(9):1050-9. PubMed ID: 17704786
[TBL] [Abstract][Full Text] [Related]
8. PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin.
Yuan Z; Yan F; Wang YS; Liu HY; Gou LT; Zhao XY; Lai ST; Deng HX; Li J; Ding ZY; Xiong SQ; Kan B; Mao YQ; Chen LJ; Wei YQ; Zhao X
Cancer Chemother Pharmacol; 2009 Dec; 65(1):13-25. PubMed ID: 19387645
[TBL] [Abstract][Full Text] [Related]
9. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies.
Apetoh L; Tesniere A; Ghiringhelli F; Kroemer G; Zitvogel L
Cancer Res; 2008 Jun; 68(11):4026-30. PubMed ID: 18519658
[TBL] [Abstract][Full Text] [Related]
10. Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir.
Alexandre J; Nicco C; Chéreau C; Laurent A; Weill B; Goldwasser F; Batteux F
J Natl Cancer Inst; 2006 Feb; 98(4):236-44. PubMed ID: 16478742
[TBL] [Abstract][Full Text] [Related]
11. Ecto-calreticulin in immunogenic chemotherapy.
Obeid M; Tesniere A; Panaretakis T; Tufi R; Joza N; van Endert P; Ghiringhelli F; Apetoh L; Chaput N; Flament C; Ullrich E; de Botton S; Zitvogel L; Kroemer G
Immunol Rev; 2007 Dec; 220():22-34. PubMed ID: 17979837
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice.
Tan Y; Sun X; Xu M; Tan X; Sasson A; Rashidi B; Han Q; Tan X; Wang X; An Z; Sun FX; Hoffman RM
Clin Cancer Res; 1999 Aug; 5(8):2157-63. PubMed ID: 10473100
[TBL] [Abstract][Full Text] [Related]
13. Suppression of dendritic cells by HMGB1 is associated with lymph node metastasis of human colon cancer.
Kusume A; Sasahira T; Luo Y; Isobe M; Nakagawa N; Tatsumoto N; Fujii K; Ohmori H; Kuniyasu H
Pathobiology; 2009; 76(4):155-62. PubMed ID: 19571604
[TBL] [Abstract][Full Text] [Related]
14. The n3-polyunsaturated fatty acid docosahexaenoic acid induces immunogenic cell death in human cancer cell lines via pre-apoptotic calreticulin exposure.
Molinari R; D'Eliseo D; Manzi L; Zolla L; Velotti F; Merendino N
Cancer Immunol Immunother; 2011 Oct; 60(10):1503-7. PubMed ID: 21779875
[TBL] [Abstract][Full Text] [Related]
15. Immunogenic cell death due to a new photodynamic therapy (PDT) with glycoconjugated chlorin (G-chlorin).
Tanaka M; Kataoka H; Yano S; Sawada T; Akashi H; Inoue M; Suzuki S; Inagaki Y; Hayashi N; Nishie H; Shimura T; Mizoshita T; Mori Y; Kubota E; Tanida S; Takahashi S; Joh T
Oncotarget; 2016 Jul; 7(30):47242-47251. PubMed ID: 27363018
[TBL] [Abstract][Full Text] [Related]
16. Colon cancer cell treatment with rose bengal generates a protective immune response via immunogenic cell death.
Qin J; Kunda N; Qiao G; Calata JF; Pardiwala K; Prabhakar BS; Maker AV
Cell Death Dis; 2017 Feb; 8(2):e2584. PubMed ID: 28151483
[TBL] [Abstract][Full Text] [Related]
17. Chemo-immunotherapy with oxaliplatin and interleukin-7 inhibits colon cancer metastasis in mice.
Gou HF; Huang J; Shi HS; Chen XC; Wang YS
PLoS One; 2014; 9(1):e85789. PubMed ID: 24465710
[TBL] [Abstract][Full Text] [Related]
18. High-mobility group box 1 protein contributes to the immunogenicity of rTcdB-treated CT26 cells.
Gu H; Liu J; Chen S; Qi H; Shi K; Li S; Ma Y; Wang J
Acta Biochim Biophys Sin (Shanghai); 2018 Sep; 50(9):921-928. PubMed ID: 30052706
[TBL] [Abstract][Full Text] [Related]
19. Targeting of insulin-like growth factor-I receptor with a monoclonal antibody inhibits growth of hepatic metastases from human colon carcinoma in mice.
Bauer TW; Fan F; Liu W; Camp ER; Yang A; Somcio RJ; Bucana CD; Singh R; Ellis LM
Ann Surg Oncol; 2007 Oct; 14(10):2838-46. PubMed ID: 17653802
[TBL] [Abstract][Full Text] [Related]
20. [Immunological aspects of anticancer chemotherapy].
Zitvogel L; Tesniere A; Apetoh L; Ghiringhelli F; Kroemer G
Bull Acad Natl Med; 2008 Oct; 192(7):1469-87; discussion 1487-9. PubMed ID: 19445369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]